Method Article

Standardization of The Rat Intraluminal MCAO Model: A Detailed Protocol with Quality Control Measures

DOI:

10.3791/69573

August 7th, 2026

* These authors contributed equally

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This protocol demonstrates an optimized 60-min middle cerebral artery occlusion (MCAO) technique in rats. The protocol is validated using multimodal approaches, achieving an 87.5% success rate with minimal mortality and yielding reproducible infarct and behavioral outcomes for stroke research.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The rat middle cerebral artery occlusion (MCAO) model remains the reference standard for elucidating ischemic stroke pathophysiology and validating neuroprotective therapies. Subtle surgical deviations, however, can profoundly alter infarct volume and behavioral outcomes. Using a "visualize-then-systematize" framework, we re-examined every step of model establishment and validation. Detailed photographic documentation of key surgical landmarks and critical steps was performed to standardize anatomical orientation and filament placement. 2,3,5-Triphenyltetrazolium chloride (TTC) staining was used to precisely map the volume and topology of infarcts at 24 h and 72 h after reperfusion. Neurological deficits were graded with the Zea-Longa, Bederson, and modified Garcia scales. Twenty-four male Sprague-Dawley rats underwent 60 min transient MCAO; infarct volume and neurological scores were assessed at 24 h and 72 h. Approximately 87.50% of animals achieved successful cerebral blood-flow blockade (Zea-Longa ≥ 1 and unequivocal TTC-defined infarct), with an overall mortality of 12.50%, attesting to the model's high fidelity. This standardized protocol provides a technically refined, reproducible foundation for preclinical stroke research, facilitating inter-laboratory consistency in studies investigating stroke pathophysiology and therapeutic interventions.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Stroke is the second leading cause of death and the third leading cause of disability worldwide1,2. Stroke disproportionately affects low- and middle-income countries, where it occurs, on average, 15 years earlier than in high-income countries1. The two main types are ischemic stroke (85%) and intracerebral hemorrhage (15%)3. Ischemic stroke, accounting for the vast majority of strokes, results from cerebral blood-flow blockage, leading to cell death and brain infarction4. The ischemic cascade involves multiple biochemical events, including significant pro-oxidative processes5,6.

Despite extensive pre-clinical and clinical efforts, only a handful of therapies—most notably intravenous thrombolysis with tissue plasminogen activator and mechanical thrombectomy—have proven efficacious, and these treatments are limited by narrow therapeutic windows and strict patient-selection criteria. Consequently, there is an urgent need to elucidate the cellular and molecular mechanisms underlying ischemic injury, neurovascular repair, and post-stroke recovery. A reproducible, clinically relevant animal model is indispensable for achieving this goal.

The middle cerebral artery occlusion (MCAO) model is broadly used to explore ischemic stroke in rodents7,8. The intraluminal filament occlusion method is one of the most classic and widely used MCAO techniques9. This technique can model both permanent and transient occlusions without requiring craniectomy. A newer transfemoral technique using endovascular wires has shown promise for inducing transient MCAO in rats, offering more consistent outcomes10. This model involves occluding the middle cerebral artery, typically using an intraluminal filament technique11. MCAO causes focal cerebral hypoperfusion, leading to ischemia and reperfusion injury12.

While MCAO is valuable for investigating stroke pathophysiology and potential treatments, it can produce variable lesion volumes7. Therefore, improvements to the MCAO model—such as refining reperfusion techniques, establishing standardized operating protocols, and developing unified evaluation criteria—can reduce variability in infarct location and volume, thereby enhancing its utility in ischemic stroke research.

This protocol requires a learning curve of approximately 10–15 surgeries to achieve consistent results13. Success rates may vary based on operator experience and rat strain14. The model is suitable for studying acute ischemic stroke but may not fully replicate human comorbidities such as hypertension or diabetes15. Accordingly, we sought to devise and rigorously validate an optimized MCAO protocol that aims to reduce experimental variability through standardized procedures and rigorous quality control measures. Four complementary innovations were integrated to achieve dual gains in standardization and data reliability: (1) Dual-time-point longitudinal assessment—neurological scores from the Zea-Longa, Bederson and Modified Garcia scales were obtained in parallel with 2,3,5-Triphenyltetrazolium chloride (TTC)-derived infarct volumes at 24 h and 72 h post-reperfusion, delineating the temporal relationship between edema resolution and functional recovery; (2) Triple-scale cross-validation—blinded, dual-investigator scoring with integrated tri-scale calibration significantly increased the sensitivity and precision of behavioral evaluation; (3) Whole-course hypothermic rapid-sectioning—a standard operating procedure (SOP) of "90 s ice bath extraction followed by single-step 2-mm coronal slicing in pre-chilled molds" was established to minimize autolysis and human error, ensuring high-fidelity volumetric measurements; (4) Integrated quality-control framework—a comprehensive SOP spanning preoperative fasting, anesthesia depth control, preoperative thermoregulation, and cross-contamination prevention was constructed to deliver a reproducible and readily transferable MCAO standard operating procedure, laying a solid foundation for inter-laboratory consistency and cross-study comparability.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The experiment was approved and supervised by the Institutional Animal Experiments and Experimental Animal Welfare Committee of Capital Medical University. All protocols complied with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publ. 80-23, 1996 rev.), and sterile equipment and aseptic techniques are required.

1. Animal selection

  1. Use male Sprague-Dawley rats (aged 6–8 weeks, weighing 240–270 g) obtained from a certified laboratory animal supplier (License No. SCXK (Beijing) 2021-0011) to establish a model of MCAO.
  2. House the animals conventionally with ad libitum food and water; all procedures followed the International Code of Ethics.
  3. Use the following criteria based on animal body weight for filament size selection to ensure consistent occlusion:
    - 220–250 g: 0.33–0.35 mm diameter
    - 250–280 g: 0.35–0.38 mm diameter
    - 280–310 g: 0.38–0.40 mm diameter
    NOTE: These specifications account for age-related increases in vessel diameter and reduce the incidence of SAH or incomplete occlusion13.

2. Sample size

  1. Calculate sample size using a sample size calculation software. Based on preliminary data showing an expected infarct volume of 35% ± 10% (mean ± SD) in the MCAO group versus 0% ± 2% in the SHAM group, estimate an effect size (Cohen's d) . For a two-tailed Mann-Whitney U test (non-parametric alternative to t-test), with α = 0.05 and power (1-β) = 0.80, calculate a minimum sample size.
    NOTE: The effect size was estimated as 3.5 and the minimum sample size was 6 animals per group.
  2. To account for anticipated mortality (12.5%) and exclusion rate (5–10%), include 24 rats in the MCAO group and 6 rats in the SHAM group, providing adequate power (>0.90) for the primary endpoint (infarct volume at 24 h).

3. Inclusion and exclusion criteria

  1. Include the animals if they met the following criteria: (1) male Sprague-Dawley rats, 240–270 g, 6–8 weeks old; (2) absence of pre-existing neurological deficits (preoperative neurological score = 0); (3) successful induction of anesthesia without complications.
  2. Exclude animals from analysis if they exhibited: (1) subarachnoid hemorrhage (SAH) evident at necropsy; (2) premature death (<24 h post-reperfusion) unrelated to experimental intervention; (3) failed occlusion (neurological score = 0 and absence of TTC-defined infarct); (4) technical surgical failure (e.g., CCA rupture).
    NOTE: These criteria were prespecified prior to study commencement to minimize selection bias.
  3. Animal replacement policy: Replace only animals excluded due to technical surgical failure or intraoperative death to maintain statistical power. Do not replace animals with unsuccessful modeling (failed occlusion) but report them as part of the success rate calculation to avoid artificially reducing variability.

4. Pre-surgical preparations

  1. Prepare autoclaved tools, sterile filament, and a draped field.
  2. No routine fasting is required; when necessary, limit the fasting duration to 2–4 h. Induce anesthesia with isoflurane (3–4%) and maintain it at 1.5–2% in 30–40% O₂ during the procedure. Confirm the depth of anesthesia by the loss of the righting reflex and toe-pinch.
  3. Maintain body temperature at 37 ± 0.5 °C using a feedback-controlled heating pad with rectal temperature monitoring.
  4. Shave the neck and scalp, then clean the area with povidone-iodine, followed by 70% ethanol.
  5. Administer buprenorphine (0.05 mg/kg, subcutaneous) 30 min prior to surgery and every 12 h postoperatively for 48 h, or meloxicam (1 mg/kg, subcutaneous) once daily for 3 days16. Assess pain by monitoring grooming behavior, posture, and spontaneous activity; provide additional analgesia if signs of discomfort persist.

5. Occlusion of the MCA

  1. Place the rat in dorsal recumbency with the head gently extended to expose the ventral neck.
  2. Make a midline cervical incision (1.5–2.0 cm) using iris scissors.
  3. Bluntly separate the sternomastoid and omohyoid muscles using curved forceps to expose the left common carotid artery (CCA) bifurcation.
  4. Ligate the external carotid artery (ECA) distally with a permanent 4-0 silk suture and proximally with a temporary ligature. Create a small incision between the two ECA ligatures using microscissors.
  5. Temporarily occlude the CCA and internal carotid artery (ICA) using microvascular clamps (60 g pressure).
  6. Insert a 4-0 silicone-coated monofilament (0.35–0.40 mm diameter) through the ECA incision. Advance it retrogradely into the CCA, then redirect it into the ICA past the CCA bifurcation.
    NOTE: Ensure the filament enters the ICA toward the cranial base, not the pterygopalatine artery (PPA) which branches laterally. If resistance is encountered at <10 mm, retract the filament, rotate the animal's head 30° toward the contralateral side, and re-advance to redirect past the PPA origin.
  7. Advance the filament 18–20 mm from the CCA bifurcation until slight resistance indicates occlusion of the MCA origin. Verify the depth using the pre-marked reference line on the filament (positioned 2 mm proximal to the silicone stopper), measured with a caliper from the ECA stump insertion point. Release the CCA clamp once the filament is in position.

6. Reperfusion

  1. After 60 min of occlusion, reopen the incision and loosen the temporary ECA ligature.
  2. Gently withdraw the filament until its tip clears the ECA stump, thereby restoring blood flow. Promptly place a permanent ligature proximal to the stump to prevent back-bleeding. Close the wound in layers.
  3. Transfer the rat to a warmed recovery cage for continuous monitoring.

7. Sham surgery

  1. Prepare the animal following the same procedure described above for MCAO (fasting, anesthesia, temperature control, sterile draping).
  2. Perform cervical incision and CCA bifurcation exposure as above.
  3. Dissect and expose the vessel. Do not insert the filament.
  4. Let the arteries remain patent; do not induce cerebral ischemia.
  5. Close the incision in layers after 10 min of exposure. Transfer the animal to a warmed recovery cage for monitoring.

8. Postoperative neurological scores

  1. Evaluate at 24 h and 72 h after reperfusion, immediately before sacrifice for infarct volume measurement.
  2. Habituate the animal in a quiet room, 25 °C for 30 min.
  3. Have two independent investigators blinded to group allocation. Have each investigator record scores on separate sheets without consultation; any inter-rater difference ≥1 point triggers re-evaluation.
  4. Scales (in order of administration): Perform Zea-Longa17(Table 1), Bederson18 (Table 2), and Modified Garcia19 (Table 3) scoring, following the latest published protocols for consistent criteria.
  5. Use the mean of the two observers for statistical analysis. Exclude data from any animal if the mean scores differ by >10% and replace with a new subject.

9. Measurement of brain infarct volume

  1. At 24 h and 72 h post-reperfusion, deeply anesthetize rats with 5% isoflurane. Confirm deep anesthesia by loss of righting reflex and toe-pinch response, together with stable respiration, before proceeding.
  2. Rapidly remove the brain within 90 s of deep anesthesia confirmation, rinse with ice-cold PBS, and cut into 2 mm coronal slices using a chilled rat brain matrix. During slicing, adhere to the following precautions
    1. Keep the entire procedure on ice at 0–4 °C; harvest the brain within 90 s and position it flat in a pre-chilled matrix.
    2. Use a sharp blade to make single, clean cuts for precise 2 mm coronal sections, collecting each slice in rostro-caudal order into ice-cold PBS.
    3. Immediately clean the matrix and blade with 75% ethanol between animals to prevent cross-contamination.
  3. After pre-warming 2% TTC to 37 °C, immerse the slices completely and incubate in the dark for 20 min, gently swirling every 5 min at 20 min.
  4. Promptly stop the reaction by rinsing three times with 4 °C PBS. Then fix in 4% paraformaldehyde at 4 °C overnight.
  5. At 300 dpi, photograph both sides of every slice once.
    1. Use fixed illumination against a white background to eliminate shadows and reflections.
    2. Lay slices flat without overlap, and include a scale bar and ID label in each frame. Hold the camera perpendicular to the sections and keep the focal length and white balance constant throughout.
  6. Quantify infarct volume using ImageJ.
    1. Import the 300 dpi image (RGB format) and convert to 8-bit grayscale (Image > Type > 8-bit).
    2. Apply Otsu's auto-thresholding (Image > Adjust > Auto Threshold > select Otsu) to separate the infarct (white) from viable tissue (red).
    3. Use the Freehand selections tool to outline the ipsilateral hemisphere boundary.
    4. Measure the area (Analyze > Measure) and record the pixel count.
    5. Calculate infarct volume: Σ (infarct area × slice thickness [2 mm]) × (contralateral hemisphere volume/ipsilateral hemisphere volume), expressed as a percentage of the contralateral hemisphere.

10. Statistical analysis

  1. Present the data as mean ± standard deviation (SD) or median [interquartile range] as appropriate.
  2. Perform between-group comparisons using the unpaired Student's t-test or Mann-Whitney U test for non-normally distributed data.
  3. Set statistical significance at P < 0.05. Conduct all analyses using an appropriate statistical analysis software.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Animals were randomly allocated to either 24 h (n = 10) or 72 h (n = 10) post-reperfusion survival groups for terminal TTC staining. An additional 4 rats underwent MCAO but died before the scheduled endpoint (mortality rate 12.5%). The SHAM group comprised n = 6. Thus, the total number of animals used was 30 (24 MCAO + 6 SHAM).

Rats underwent 60-min MCAO to induce cerebral ischemia (Figure 1). Reperfusion was initiated by removing the intraluminal filament and releasing the proximal ligature at ECA. Among the 24 MCAO rats, 3 died within 72 h; one showed extensive infarction upon post-mortem TTC staining within 24 h, while the other died of undetermined causes within 72 h. Two additional rats were excluded due to unsuccessful modeling (neurological scores did not meet criteria, and TTC staining revealed no infarct). Thus, the 72 h mortality rate was 12.50%. We defined successful model establishment as survival for 24 h plus a Longa score of 1–3 and the successful modeling rate reached 87.50%.

Neurological function was evaluated at 24 h and 72 h after stroke onset (before infarct volume measurement). Three most commonly used scales reported in the literature—Zea-Longa, Bederson, and modified Garcia—were employed to provide a comprehensive assessment (Figure 2). At 24 h, the rats (n = 20) scored 2.02 ± 0.41 on the Zea-Longa scale, 2.80 ± 0.41 on the Bederson scale, and 8.15 ± 1.18 on the modified Garcia scale; these deficits remained pronounced at 72 h (Zea-Longa: 1.65 ± 0.59; Bederson: 1.93 ± 0.38; modified Garcia: 11.00 ± 1.34). Infarct volume, expressed as a percentage of the contralateral hemisphere, was 37.61 ± 2.81% at 24 h after MCAO and decreased to 28.32 ± 4.18% at 72 h.

Diagram of rat cervical vessel anatomy, ICA, ECA, MCA, PPA. Anatomical variations comparison.
Figure 1: Schematic diagram of left cervico-cerebral arterial physiology and middle cerebral artery embolism in the rat. Schematic diagram of (A) cervico-cerebral arterial anatomy, (B) pre-insertion, (C) post-insertion, and (D) filament malposition into the pterygopalatine artery. CCA: common carotid artery; ICA: internal carotid artery; ECA: external carotid artery; PPA: pterygopalatine artery; MCA: middle cerebral artery. "Black triangle": the incision site; blue line: the filament. Please click here to view a larger version of this figure.

Rat cerebral infarction analysis; TTC staining, graph of infarct volume, line charts of scores.
Figure 2: Infarct volume measurement and neurological behavioral assessment after cerebral artery occlusion in rats. (A) TTC staining of brain sections. (B) The infarct volume at 72 h is smaller than that at 24 h. (C,D) The Zea-Longa scores and Bederson scores at 72 h are lower than those at 24 h. (E) The modified Garcia scores at 72 h are higher than those at 24 h. ****P < 0.0001, ***P < 0.001, **P < 0.01. Please click here to view a larger version of this figure.

ManifestationScore / points
No neurological deficit0
Contralateral forelimb flexed and adducted during tail suspension (mild neurological deficit)1
Spontaneous circling toward the contralateral side while crawling (moderate neurological deficit)2
Falling to the contralateral side when standing or walking3
(severe neurological deficit)
No spontaneous movement accompanied by impaired consciousness4

Table 1: Zea-Longa score.

ManifestationScore/points
Grasp the animal’s tail and lift it so that the body is suspended 10 cm above the bench. In normal rats, both forelimbs remain extended toward the floor. Rats with neurological deficits may exhibit the following behaviors:
No neurological deficit0
The paretic forelimb is flexed and held close to the abdomen, while the unaffected limb extends toward the bench1
In addition to the behavior described in 1, resistance to lateral push toward the paretic side is markedly reduced when the animal is placed prone on the bench2
In addition to the behaviors described in 1 and 2, the animal circles toward the paretic side while walking3

Table 2: Bederson score.

ItemManifestationScore/points
a)     Spontaneous MovementNormal activity 3
(Observe the rat’s activity in its home cage for 5 min)Slightly impaired 2
Moderately impaired 1
No spontaneous movement0
b)    Symmetrical Limb MovementSymmetrical posture 3
Asymmetrical posture 2
Hemiplegia1
c)     Forelimb OutstretchingSymmetrical3
(Grasp the tail and bring the forelimbs toward the edge of the table; observe forepaw extension)Mildly asymmetrical  2
Markedly asymmetrical1
Hemiplegia0
d)    Grip and climbing abilityClimbs strongly with firm grip3
Unilateral deficit observed2
Unable to climb or circles1
e)     Bilateral tactile reflex on the bodySymmetrical on both sides3
Sluggish response on one side2
No response on one side1
f)     Bilateral vibrissae touch responseSymmetrical3
Asymmetrical2
No response1

Table 3: Modified Garcia score. Total score: 0–18 points; higher scores indicate better neurological function.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

It is important to clarify that the primary objective of this study was methodological standardization rather than biological discovery. Developing a standardized MCAO protocol is vital for reducing inter-laboratory variability and enhancing reproducibility in ischemic stroke research. This protocol enhances procedural transparency through rigorous quality control measures and addresses common technical deficiencies in MCAO modeling, including standardized filament insertion, temperature regulation, and histological processing.

While the observed reduction in infarct volume from 24 h to 72 h and partial neurological recovery represent expected pathophysiological phenomena in transient MCAO, the contribution of this study lies in establishing the temporal reliability of these endpoints using a rigorously standardized procedure. By providing a detailed, stepwise technical framework, this protocol ensures that future mechanistic studies—whether investigating neuroinflammatory cascades, apoptotic pathways, or therapeutic interventions—are built upon reproducible and comparable baseline data. We explicitly position this work as a technical resource consistent with JoVE's scope, providing a foundation for standardized preclinical stroke research rather than advancing mechanistic insights.

Several steps in this protocol are particularly crucial for ensuring consistent ischemia and reperfusion. Firstly, precisely advancing the occlusion line until a slight resistance is felt is essential for achieving reproducible MCAO, as a minor deviation in insertion depth can lead to incomplete occlusion or subarachnoid hemorrhage20,21. Secondly, maintaining a strict intraoperative normal body temperature (37 ± 0.5 °C) and postoperative temperature management is crucial, as either too low or too high a body temperature can significantly alter the infarct area and neurological outcome12,22. Thirdly, rapidly removing the brain within 90 s and performing ice bath cooling can minimize autolysis and maintain tissue integrity, thereby ensuring the accuracy of TTC staining and volume analysis23. If these steps can be consistently implemented, they will significantly improve model fidelity and comparability between studies.

We have improved the traditional MCAO method to enhance its reproducibility and ease of use. The use of pre-cooled brain slice molds and standardized slicing protocols has reduced human errors and slice artifacts. Additionally, the adoption of a three-scale (Zea-Longa, Bederson, and modified Garcia) neurological function assessment by two blinded researchers has increased the robustness and sensitivity of the functional assessment17,18,19. Through detailed standard operating procedures covering each program stage, it helps to identify common problems such as filament malposition, premature reperfusion, or postoperative hypothermia. Troubleshooting guidance for common complications includes: (1) Misplaced occlusion line (PPA entry), recognized by lack of resistance at 10–12 mm and immediate neurological improvement—if encountered, immediately retract the filament, rotate the animal's head 30° toward the contralateral side, and re-advance with slight medial angulation toward the cranial base; (2) Premature reperfusion, indicated by sudden neurological improvement during occlusion—ensure the silicone stopper is securely fixed at the ECA stump, verify filament diameter matches the artery size (0.35–0.40 mm for 240–270 g rats), and consider using a longer filament (increase silicone coating by 0.5 mm) if displacement persists; and (3) Postoperative hypothermia (rectal temperature <36ºC)—increase the heating pad temperature to 38 °C, place a heat lamp 30 cm above the animal, and administer warm sterile saline (0.5 mL, intraperitoneally, 37ºC).

Despite these advancements, this protocol has several limitations. First, the technique requires a substantial learning curve (10–15 surgeries) to achieve consistent success rates, and individual variations in rat vascular anatomy may affect filament placement21,24. Second, the present protocol relies on post-hoc verification (neurological scoring and TTC staining) rather than intraoperative cerebral blood flow monitoring (LDF or LSCI), which limits quality control during surgery and precludes early exclusion of animals with incomplete occlusion25. Third, validation was limited to young male Sprague-Dawley rats, restricting generalizability to females, aged animals, and comorbid models26,27. Future studies should incorporate: (1) both sexes to address sex as a biological variable; (2) aged rats (12–18 months) with vascular comorbidities; and (3) real-time CBF monitoring to enhance reproducibility in drug intervention studies.

This method is particularly valuable in preclinical drug screening as the consistency and translational relevance of its results are of crucial importance. The standardized protocol described in this article holds great promise for enhancing the rigor and reproducibility of ischemic stroke research. Future applications of this protocol include: (1) preclinical screening of neuroprotective agents administered during the reperfusion window; (2) mechanistic studies of ischemia-reperfusion injury using the 24 h and 72 h time points; (3) investigation of post-stroke neuroplasticity and functional recovery; and (4) validation of therapeutic targets in combination with genetic or pharmacological interventions. By providing detailed and video-supported SOP, our aim is to facilitate the widespread adoption of this method in laboratories of various professional levels, ultimately contributing to more reliable and clinically relevant preclinical stroke research.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have nothing to disclose.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

This work was supported by the Beijing Natural Science Foundation (No.7232269) and the Beijing Traditional Chinese Medicine Science and Technology Development Fund Project (No. JJ-2023-93).

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
2% TTC staining solutionBeijing Solarbio Science & Technology Co., Ltd.T817025 g/bottle, ≥98 % purity
4% PFABeijing Solarbio Science & Technology Co., Ltd.P1110500 mL ready-to-use
Absorbable sutureShandong Weigao Group Medical Polymer Co., Ltd.VCP345H5-0 Vicryl
Adson forcepsShanghai Jinzhong Surgical Instrument Co., Ltd.JD-110101×2 teeth, 12 cm
Dumont curved forcepsShanghai Jinzhong Surgical Instrument Co., Ltd.JD-1105211 cm length, 0.05 mm fine tip
Feedback heating padShenzhen Reward Life Science & Technology Co., Ltd.6900137 ± 0.3 °C closed loop
ImageJNational Institutes of Healthversion 1.53k
Iris scissorsShanghai Jinzhong Surgical Instrument Co., Ltd.JD-14060Curved tip, 10 cm
Micro-vascular clipsShenzhen Ruiwode Lift Technology Co.,Ltd.JD-160101.5 cm curved clip
Non-absorbable silkShanghai Pudong Jin-Huan Medical Products Co., Ltd.S-23046-0 Black silk thread
PASS software NCSS, LLC, Kaysville, UT, USAversion 15.0 Sample size calculation software 
Rat brain matrixShenzhen Ruiwode Lift Technology Co.,Ltd.686102 mm coronal slots
Silicone-coated nylon filamentShenzhen Ruiwode Lift Technology Co.,Ltd.60-12500.35 mm OD, 30 mm silicone tip, EO-sterile
Small-animal anesthesia machineShenzhen Ruiwode Lift Technology Co.,Ltd.R500IEIsoflurane vaporizer, induction chamber & mask included
SPSSIBM Corp., Armonk, NY, USAversion 26.0 Statistical analysis software
Vannas micro-scissorsShanghai Jinzhong Surgical Instrument Co., Ltd.JD-14058Curved tip, 8 cm

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Walter, J., Oyere, O., Mayowa, O., Sonal, S. Stroke: a global response is needed. Bull World Health Organ. 94 (9), 1816-1834 (2016).
  2. Mira, K., Andreas, L. Global burden of stroke. Semin Neurol. 38 (2), 1649-2211 (2018).
  3. Stephen, J. M., David, J. W. Stroke: causes and clinical features. Medicine (Abingdon). 48 (9), 1561-1566 (2020).
  4. Narayanaswamy, V. Ischemic stroke: new insights from risk factors, mechanisms and outcomes. J Cardiovasc Dev Dis. 10 (12), 472(2023).
  5. Chao, L., Tao, S., Chen, J. Recent advances in nanomedicines for the treatment of ischemic stroke. Acta Pharm Sin B. 11 (7), 1767-1788 (2021).
  6. Marcelo, F., Leonardo, E. V., Brigitta, B., Elisabetta, P., Luciano, S. The nrf2 pathway in ischemic stroke: a review. Molecules. 26 (16), 5001(2021).
  7. Melissa, T. -L., Claire, L. G. A review of experimental models of focal cerebral ischemia focusing on the middle cerebral artery occlusion model. F1000Res. 10, 51752(2021).
  8. Lang, Z., et al. Animal models of ischemic stroke with different forms of middle cerebral artery occlusion. Brain Sci. 13 (7), 1007(2023).
  9. Rosalia, C., Rosanna, D. P., Emanuela, E., Salvatore, C. Middle cerebral artery occlusion by an intraluminal suture method. Methods Mol Biol. 1727, 1393-1401 (2018).
  10. Afshin, A. D., et al. Transfemoral approach to induce transient middle cerebral artery occlusion in rats: the use of commercially available endovascular wires. Neurocrit Care. 32 (2), 575-585 (2020).
  11. Seunghoon, L., et al. Middle cerebral artery occlusion methods in rat versus mouse models of transient focal cerebral ischemic stroke. Neural Regen Res. 9 (7), 1315-1318 (2014).
  12. Kitti, T., Nipon, C., Siripron, C. C. The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion. J Cell Physiol. 236 (3), 21677-21694 (2021).
  13. Gary, P. M., et al. A comparative study of variables influencing ischemic injury in the longa and koizumi methods of intraluminal filament middle cerebral artery occlusion in mice. PLoS One. 11 (2), e0148503(2016).
  14. J, S., et al. Strain differences in intraluminal thread model of middle cerebral artery occlusion in rats. Physiol Res. 68 (1), 933937-933948 (2019).
  15. Chang, L., Xiaoqing, W., Yueru, Z., Songli, Y., Xiangshi, T. Study on the efficacy and pharmacological mechanism of innate immune sting pathway regulators in the treatment of ischemic brain injury. Pharmaceuticals. 18 (12), 1775(2025).
  16. Pei-Kang, L., et al. Neuroprotective effects of low-dose G-CSF plus meloxicam in a rat model of anterior ischemic optic neuropathy. Sci Rep. 10 (1), 66977(2020).
  17. Longa, E. Z., Weinstein, P. R., Carlson, S., Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20 (1), 1184-1191 (1989).
  18. Bederson, J. B., et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17 (3), 1472-1476 (1986).
  19. David, W. H., et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab. 30 (8), 1412-1431 (2010).
  20. Kudret, T., Raghu, V., Kurt, A. S., Robert, J. D. Ideal suture diameter is critical for consistent middle cerebral artery occlusion in mice. Neurosurgery. 56 (1 Suppl), 196-200 (2005).
  21. Ilya, L. G., et al. MRI guiding of the middle cerebral artery occlusion in rats aimed to improve stroke modeling. Transl Stroke Res. 9 (4), 12417-12425 (2018).
  22. Nathalie, P. D. S., et al. The IMPROVE guidelines (Ischaemia models: procedural refinements of in vivo experiments). J Cereb Blood Flow Metab. 37 (11), 17703488-17703517 (2017).
  23. Chintamani, N. J., Swatantra, K. J., Puvvada, S. R. M. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Protoc. 13 (1), 1011-1017 (2004).
  24. Huaxin, S., Lihong, D., Xuan, L., Zhong, Y., Wei, Y. A modified transcranial middle cerebral artery occlusion model to study stroke outcomes in aged mice. J Vis Exp. (195), e65345(2023).
  25. Maria, S., et al. Modified middle cerebral artery occlusion model provides detailed intraoperative cerebral blood flow registration and improves neurobehavioral evaluation. J Neurosci Methods. 358, 109179(2021).
  26. Clemens, J. S. Ischemic stroke: experimental models and reality. Acta Neuropathol. 133 (2), 245-261 (2017).
  27. Bharti, M., Louise, D. M. Sexual dimorphism in ischemic stroke: lessons from the laboratory. Womens Health (Lond). 7 (3), 2222-2239 (2011).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

NeuroscienceKeywords Ischemic strokemiddle cerebral artery occlusionReperfusionintraluminal filamentintraluminal suture

Related Articles